pntd.0006440.g002.tif (1.42 MB)
Comparison of prescribing restrictions for primaquine and tafenoquine under three different scenarios broken down by gender.
figure
posted on 2018-04-20, 17:33 authored by James Watson, Walter R. J. Taylor, Germana Bancone, Cindy S. Chu, Podjanee Jittamala, Nicholas J. WhiteThis assumes that 10% of heterozygous females would test deficient at screens with a 30% activity threshold, and 70% of heterozygous females and 5% of all wild type individuals at a 70% threshold. Top left: current proportions of individuals ineligible for radical cure for vivax malaria following G6PD deficiency testing; top right: proportions of individuals ineligible for radical cure if primaquine and tafenoquine could be given to females breast-feeding infants older than 1 month; bottom left: proportions of individuals ineligible for radical cure if primaquine could be given to G6PD deficient persons.
History
Usage metrics
Categories
Keywords
restrictionG 6PDd allele frequencythresholdG 6PD activityMethods Quantitative G 6PD enzyme activity dataglucose -6-phosphate dehydrogenasevivax malaria BackgroundG 6PDprimaquinewomen breast-feeding infantsindividualG 6PD deficiencycure antimalarial regimenspopulation coveragetafenoquine8- aminoquinoline antimalarials
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC